Prelude Therapeutics (PRLD)
NASDAQ:PRLD
Top Page
Prelude Therapeutics
(NASDAQ:PRLD)
Select Model
Select Model
Rating:60Neutral
Price Target:
$4.00
▲(63.27% Upside)
Action:ReiteratedDate:03/13/26
The score is supported by improving technical momentum and a constructive earnings-call outlook (pipeline advancement and the Incyte partnership improving runway/validation). These positives are tempered by weak financial performance driven by large ongoing losses and cash burn, plus limited valuation support given the negative P/E and no dividend.
Positive Factors
Incyte collaboration & upfront funding
A large, structured collaboration with Incyte supplies meaningful non‑dilutive (and staged) capital and strategic validation from a major pharma partner. This materially extends runway, reduces near‑term financing pressure and strengthens partnering optionality for late preclinical/early clinical assets.
Negative Factors
High operating cash burn
Persistently negative operating and free cash flow means the business cannot self‑fund R&D and trials; ongoing burn requires material external capital. That reliance increases financing risk, potential dilution and constrains strategic flexibility if clinical timelines slip or partner payments are delayed.
Read all positive and negative factors
Positive Factors
Negative Factors
Incyte collaboration & upfront funding
A large, structured collaboration with Incyte supplies meaningful non‑dilutive (and staged) capital and strategic validation from a major pharma partner. This materially extends runway, reduces near‑term financing pressure and strengthens partnering optionality for late preclinical/early clinical assets.
Read all positive factors
Prelude Therapeutics (PRLD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$231.85M
Dividend YieldN/A
Average Volume (3M)256.05K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth250.00%
EPS Growth15.15%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding48,274,113
10 Day Avg. Volume194,393
30 Day Avg. Volume256,051
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.25
Price to Sales (P/S)18.38
P/FCF Ratio-3.96
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue18.76
Enterprise Value/Gross Profit20.16
Enterprise Value/Ebitda-2.23
Forecast
1Y Price Target
$6.00Price Target Upside144.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$50.00M
Prelude Therapeutics Business Overview & Revenue Model
Company Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in sel...
How the Company Makes Money
Prelude Therapeutics primarily generates revenue, when applicable, through collaboration and licensing arrangements (e.g., upfront payments, research funding, milestone payments tied to development/regulatory/commercial events, and potential royal...
Prelude Therapeutics Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Neutral
The earnings call highlights strategic advancements and a strong financial partnership with Incyte, positioning Prelude well for future development. However, challenges remain in differentiating their products in competitive spaces and ensuring timely clinical progress.Positive Updates
Strategic Decisions and Financial Position
Prelude Therapeutics has made strategic decisions to focus on R&D, optimize capital allocation, and align business strategy with high-probability success programs. These efforts have strengthened their financial position, providing additional cash runway into 2027.
Negative Updates
Potential Competition
The presence of competitors in both JAK2 and KAT6A spaces, including established players like Pfizer, poses a challenge in differentiating Prelude's offerings.
Read all updates
Q3-2025 Updates
Positive
Negative
Strategic Decisions and Financial Position
Prelude Therapeutics has made strategic decisions to focus on R&D, optimize capital allocation, and align business strategy with high-probability success programs. These efforts have strengthened their financial position, providing additional cash runway into 2027.
Read all positive updates
Company Guidance
During the Prelude Therapeutics Investor Conference Call, the company provided guidance on its strategic focus and future clinical development activities. Prelude is set to advance two key development candidates into clinical trials by 2026: a JAK2V617F selective inhibitor for myeloproliferative neoplasms (MPN) and a KAT6A selective degrader for ER-positive breast cancer. The JAK2V617F inhibitor targets a mutation present in over 95% of polycythemia vera patients and 50-60% of patients with myelofibrosis and essential thrombocythemia, representing a market of over 200,000 MPN patients in the U.S. alone. The KAT6A program aims to address resistance in ER-positive breast cancer, with preclinical data suggesting a differentiated safety and efficacy profile over existing treatments. Prelude announced a significant $910 million deal with Incyte, including an upfront payment of $60 million, providing a financial runway into 2027, and plans to file an Investigational New Drug (IND) application for the JAK2 program in early 2026.Prelude Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
50
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 12.14M | 7.00M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 10.43M | 7.00M | 0.00 | 0.00 | 0.00 |
| EBITDA | -102.86M | -137.94M | -131.11M | -122.22M | -112.82M |
| Net Income | -99.50M | -127.17M | -121.83M | -115.44M | -111.69M |
Balance Sheet | |||||
| Total Assets | 141.31M | 175.51M | 277.67M | 220.50M | 305.10M |
| Cash, Cash Equivalents and Short-Term Investments | 103.21M | 133.61M | 232.94M | 201.73M | 291.23M |
| Total Debt | 17.79M | 18.02M | 16.89M | 1.83M | 1.74M |
| Total Liabilities | 72.68M | 44.06M | 40.58M | 25.06M | 19.20M |
| Stockholders Equity | 68.64M | 131.46M | 237.09M | 195.44M | 285.90M |
Cash Flow | |||||
| Free Cash Flow | -56.37M | -103.65M | -110.58M | -86.75M | -85.85M |
| Operating Cash Flow | -56.30M | -102.89M | -107.06M | -83.73M | -83.53M |
| Investing Cash Flow | 53.46M | 90.19M | -34.65M | 81.69M | -263.80M |
| Financing Cash Flow | 24.82M | -120.00K | 136.40M | 815.00K | 164.90M |
Prelude Therapeutics Technical Analysis
Positive
2.45
Price Trends
2.76
Positive
2.35
Positive
1.75
Positive
Market Momentum
0.17
Negative
63.77
Neutral
72.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRLD, the sentiment is Positive. The current price of 2.45 is below the 20-day moving average (MA) of 3.31, below the 50-day MA of 2.76, and above the 200-day MA of 1.75, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 63.77 is Neutral, neither overbought nor oversold. The STOCH value of 72.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRLD.
Prelude Therapeutics Risk Analysis
Prelude Therapeutics disclosed 77 risk factors in its most recent earnings report. Prelude Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prelude Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $231.85M | -2.24 | -129.98% | ― | 250.00% | 15.15% | |
53 Neutral | $69.33M | -0.84 | -59.07% | ― | ― | -58.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $78.57M | -5.27 | -237.54% | ― | ― | 42.29% | |
40 Underperform | $22.85M | -1.78 | 774.80% | ― | -8.16% | 22.44% |
* Healthcare Sector Average
PRLD
Prelude Therapeutics
3.68
3.07
503.28%
PSTV
Plus Therapeutics
3.33
-16.67
-83.35%
PMVP
PMV Pharmaceuticals
1.30
0.40
44.44%
GANX
Gain Therapeutics
1.86
0.28
17.72%
IMMX
Immix Biopharma
8.59
7.23
531.62%
Prelude Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Prelude Therapeutics Establishes New ATM Equity Offering Facility
Positive
Mar 12, 2026
Prelude Therapeutics said that, under a previously established Open Market Sale Agreement with Jefferies LLC, it has the ability to issue and sell up to $75 million of its common stock. On March 12, 2026, the company filed a prospectus supplement ...
Business Operations and StrategyFinancial Disclosures
Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program
Positive
Mar 10, 2026
Prelude Therapeutics reported full-year 2025 financial results on March 10, 2026, and outlined a 2026 program roadmap centered on its JAK2V617F and KAT6A programs. The company ended 2025 with $106.4 million in cash and equivalents, expects its cas...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Prelude Therapeutics Wins FDA IND Clearance for PRT12396
Positive
Feb 3, 2026
On February 3, 2026, Prelude Therapeutics announced that the U.S. Food and Drug Administration had cleared its Investigational New Drug application for PRT12396, a mutant-selective JAK2V617F inhibitor designed to treat certain myeloproliferative n...
Business Operations and Strategy
Prelude Therapeutics unveils strategic investor presentation on pipelines
Positive
Jan 9, 2026
On January 9, 2026, Prelude Therapeutics began using a new corporate investor presentation outlining its strategy to advance two highly differentiated programs: JAK2V617F mutant-selective JH2 inhibitors for myeloproliferative neoplasms and first-i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.